T
Thomas F. Lüscher
Researcher at University of Zurich
Publications - 1613
Citations - 88517
Thomas F. Lüscher is an academic researcher from University of Zurich. The author has contributed to research in topics: Endothelium & Myocardial infarction. The author has an hindex of 134, co-authored 1560 publications receiving 79034 citations. Previous affiliations of Thomas F. Lüscher include University of Texas Southwestern Medical Center & Durham University.
Papers
More filters
Journal ArticleDOI
Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional β1-blockade.
Sajoscha A. Sorrentino,Carola Doerries,Costantina Manes,Thimoteus Speer,Chantal Dessy,Irina Lobysheva,Wazma Mohmand,Razma Akbar,Ferdinand H. Bahlmann,Christian Besler,Arnd Schaefer,Denise Hilfiker-Kleiner,Thomas F. Lüscher,Jean-Luc Balligand,Helmut Drexler,Ulf Landmesser +15 more
TL;DR: Nebivolol improves LV dysfunction and survival early after MI likely beyond the effects provided by conventional β₁-receptor blockade, and was associated with improved survival 4 weeks post-MI compared with placebo.
Journal ArticleDOI
Three decades of endothelium research: from the detection of nitric oxide to the everyday implementation of endothelial function measurements in cardiovascular diseases.
TL;DR: This overview aims to provide a glimpse into this fascinating research field with the emphasis on vasoactive substances and the assessment of endothelial function.
Journal ArticleDOI
Novel findings in neutrophil biology and their impact on cardiovascular disease.
Aldo Bonaventura,Aldo Bonaventura,Fabrizio Montecucco,Franco Dallegri,Federico Carbone,Thomas F. Lüscher,Thomas F. Lüscher,Giovanni G. Camici,Luca Liberale,Luca Liberale +9 more
TL;DR: Novel findings in neutrophil biology are discussed, their impact on CV and cerebrovascular diseases, and the potential implementation of these notions into daily clinical practice.
Journal ArticleDOI
Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata.
Chad Brokopp,Roman Schoenauer,Peter J. Richards,Stefan Bauer,Christine Lohmann,Maximilian Y. Emmert,Benedikt Weber,Stephan Winnik,Elena Aikawa,K Graves,Michele Genoni,Peter Vogt,Thomas F. Lüscher,Christoph Renner,Simon P. Hoerstrup,Christian M. Matter +15 more
TL;DR: Fibroblast activation protein associates with thin-cap human coronary fibroatheromata and contributes to type I collagen breakdown in fibrous caps and is induced by macrophage-derived TNFα.
Journal ArticleDOI
Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells.
Christian M. Matter,Izabela Rozenberg,Andrea Jaschko,Helen Greutert,David J. Kurz,Stephan Wnendt,Bernd Kuttler,Hana Joch,Jürg Grünenfelder,Gregor Zünd,Felix C. Tanner,Thomas F. Lüscher +11 more
TL;DR: Tacrolimus is less potent than sirolimus for inhibiting VSMC proliferation or migration, but exerts markedly less antiproliferative effects on EC compared with sIROlimus, and may represent a promising compound for the use in drug-eluting stents.